Decision Making SIG


The Quantitative Decision-making Special Interest Group (QDM SIG) was formed in October 2017. It is a group of statisticians from industry and academia, with experience and interests in statistical methods for quantitative decision-making in drug development. The objectives of the SIG are:

  • To share (anonymized) case studies of how quantitative decision-making methods have been used within pharmaceutical companies, for decisions at the trial level, at the development level and at the portfolio level
  • To perform literature reviews, discuss and make recommendations on existing methodologies in terms of approach and interpretation
  • To develop new methodologies or practices where needed
  • To promote the role of the statistician in supporting decision-making in pharmaceutical companies and/or other stakeholders
  • To propose trainings, public meetings or publications to share methods and experience

Who we are

Gianluca Baio (UCL)
Nicolas Bonnet (Sanofi)
Sarah Bray (Amgen)
Alex Carlton (GSK)
Jacquie Christie (GSK)
Pierre Colin (Debiopharm)
Paul Frewer (AstraZeneca)
Heiko Goette (Merck)
Martin Johnson (UCB Pharma)
Kevin Kunzmann (Cambridge University)
John-Philip Lawo (CSL Behring)
Jesper Madsen (Novo Nordisk)
Pavel Mozgunov (Lancaster University)
Emmanuel Pham (Ipsen)
Veronique Robert (Servier)
Oliver Sailer (Boehringer Ingelheim )
Gaëlle Saint-Hilary (Saryga) (Chair)
Guido Thömmes (Grunenthal)

How to get in touch

For further information, or to join the QDM SIG, please contact the chair:

Gaelle Saint-Hilary (Saryga)

Latest News


Upcoming Events


Upcoming Events

Latest Jobs